SCHEDULE 13G/A: Janus Henderson Group PLC Discloses 11.2% Stake in Soleno Therapeutics

Janus Henderson Group PLC has filed an amended Schedule 13G, revealing a beneficial ownership of 11.2% of Soleno Therapeutics, Inc.'s common stock as of March 31, 2025.

Summary

• Janus Henderson Group PLC, a Jersey-based parent holding company and investment adviser, has filed an Amendment No. 5 to Schedule 13G regarding its beneficial ownership in Soleno Therapeutics, Inc.
• As of March 31, 2025, Janus Henderson Group PLC beneficially owns 5,152,669 shares of Soleno Therapeutics' common stock.
• This ownership represents 11.2% of the class of Soleno Therapeutics' common stock.
• The filing indicates that Janus Henderson Group PLC holds shared voting power and shared dispositive power over these shares.
• The shares are held in the ordinary course of business and were not acquired or held for the purpose of changing or influencing control of the issuer.
• Indirect subsidiaries of Janus Henderson, including JHIUS, JHIUKL, and JHIAIFML, are registered investment advisers furnishing investment advice to Managed Portfolios, with JHIUS specifically deemed beneficial owner of 5,103,513 shares (11.1% of class).

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing a significant passive ownership stake. It contains no information that would inherently suggest a positive or negative outlook for the issuer's business operations or financial performance.

Positives

• A significant institutional investor, Janus Henderson Group PLC, maintains a substantial stake in Soleno Therapeutics, indicating continued confidence or strategic interest.
• The filing confirms that the shares are held in the ordinary course of business, suggesting a passive investment rather than an activist intent to influence control.

Future Outlook

The document, a Schedule 13G filing, does not provide any forward-looking statements or guidance regarding Soleno Therapeutics, Inc.'s future performance or operations. It solely reports on beneficial ownership.

Management Comments

• Kristin Mariani, Head of North America Compliance, CCO for Janus Henderson Group PLC, certified that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This Schedule 13G filing indicates a significant passive investment by a major institutional asset manager, Janus Henderson Group PLC, in Soleno Therapeutics. Such filings are standard disclosures required by the SEC when an entity acquires more than 5% of a company's voting class of securities, signaling a notable institutional presence on the shareholder register.

Stakeholder Impact

• Shareholders of Soleno Therapeutics, Inc. are informed of a significant institutional investor's stake, which can influence market perception and liquidity.
• Potential investors gain transparency regarding the ownership structure of Soleno Therapeutics, Inc.

Next Steps

• Janus Henderson Group PLC will be required to file further amendments to Schedule 13G if there are material changes to their beneficial ownership of Soleno Therapeutics, Inc. shares.

Key Dates

Keywords

Soleno Therapeutics, Janus Henderson Group PLC, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Equity Stake, Investment Adviser